Cerevel Therapeutics (CERE) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CERE shares.
View CERE analyst ratings or view top-rated stocks.

10 analysts have issued twelve-month price objectives for Cerevel Therapeutics' shares. Their CERE share price forecasts range from $22.00 to $46.00. On average, they predict the company's share price to reach $34.00 in the next year. This suggests a possible upside of 67.8% from the stock's current price.
View analysts price targets for CERE or view top-rated stocks among Wall Street analysts.

Cerevel Therapeutics' stock was trading at $31.54 at the beginning of the year. Since then, CERE stock has decreased by 35.8% and is now trading at $20.26.
View the best growth stocks for 2023 here.

Cerevel Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 5,440,000 shares, an increase of 7.1% from the August 15th total of 5,080,000 shares. Based on an average daily volume of 635,600 shares, the days-to-cover ratio is presently 8.6 days. Currently, 7.9% of the company's stock are short sold.
View Cerevel Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CERE earnings forecast.

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.02. During the same period last year, the business posted ($0.61) earnings per share.

ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN), Principal Healthcare Innovators ETF (BTEC), Harbor Health Care ETF (MEDI) and Fidelity Disruptive Medicine ETF (FMED).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."

Cerevel Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.41%), BlackRock Inc. (3.08%), State Street Corp (1.76%), Artal Group S.A. (1.04%), Geode Capital Management LLC (0.86%) and Polar Capital Holdings Plc (0.58%). Insiders that own company stock include Abraham Ceesay, Deval L Patrick, Gabrielle Sulzberger, John Renger, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc and Ronald C Renaud Jr.
View institutional ownership trends.

Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CERE stock can currently be purchased for approximately $20.26.

Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $3.19 billion. The biotechnology company earns $-351,510,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

The company employs 322 workers across the globe.

Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for the company is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at ir@cerevel.com.